Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of SCT1000 in Healthy Women
NCT05060484Phase 2Unknown
- Sponsor
- Sinocelltech Group Limited
- Start
- Oct 2021
- Primary completion
- May 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant 14-valent human papillomavirus vaccine in human papillomavirus infection, sponsored by Sinocelltech Group Limited. Status: unknown.
02
Drugs
recombinant 14-valent human papillomavirus vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT05060484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05060484.